Update on the Management of Breast Cancer during Pregnancy

• Published in: Cancers Vol. 12; no. 12; p. 3616
• Main Authors: Poggio, Francesca, Tagliamento, Marco, Pirrone, Chiara, Soldato, Davide, Conte, Benedetta, Molinelli, Chiara, Cosso, Maurizio, Fregatti, Piero, Del Mastro, Lucia, Lambertini, Matteo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 03.12.2020; MDPI
• Subjects: Antitumor agents; Biology; Biopsy; Breast cancer; Cancer therapies; Chemotherapy; Contraindications; Cytotoxicity; Drug dosages; Endocrine therapy; Fetuses; Genomes; Gestational age; Lymphatic system; Medical prognosis; Mutation; Patients; Pregnancy; pregnancy during breast cancer; Radiation therapy; radiotherapy; Review; Surgery; Womens health; targeted therapy; pregnancy during breast cancer; immunotherapy; pregnancy; radiotherapy; breast cancer; chemotherapy; endocrine therapy; surgery
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12123616

The diagnosis of breast cancer during pregnancy represents a challenging situation for the patient, her caregivers and physicians. Pregnancy adds complexity to oncological treatment planning, as many therapies can be potentially dangerous to the fetus. Therefore, a multidisciplinary approach is needed to offer a proper care for obtaining the best possible outcomes for the mother and the future child. Breast surgery is feasible throughout the pregnancy while radiotherapy should be postponed after delivery. Administration of chemotherapy is considered safe and can be given during the second and third trimesters, while it is contraindicated in the first trimester due to the high risk of fetal malformations. Endocrine therapy and targeted agents are not recommended during the whole pregnancy period; however, limited data are available on the use of the majority of new anticancer drugs in this context. The aim of the current review is to provide an update on the current state of art about the management of women diagnosed with breast cancer during pregnancy.